CTS-1027: Interim Phase II data

Interim data from 61 evaluable patients in an ongoing, single-arm, open-label, U.S. Phase II trial showed that twice-daily 15 mg CTS-1027 plus Pegasys peginterferon alfa-2a and Copegus ribavirin led...